Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This study reported that in mice with rapamycin-induced thymic atrophy, Angelica sinensis promoted thymic cortical regeneration and functional recovery by activating the Wnt/CTNNB1/Foxn1 signaling pathway and improving inflammatory microenvironment, suggesting its potential benefit against immune aging.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

This study outlines treatment options for alopecia, suggesting intralesional corticosteroids for localized adult cases and Janus Kinase inhibitors for severe cases, emphasizing a balance between hair regrowth rate and managing side effects.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This review discusses the regenerative potential of hair follicle stem cell populations and current approaches to reconstructing folliculogenesis for alopecia therapy, but reports no new clinical results.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This study reviewed the literature on atopic dermatitis and found a strong connection with several other skin conditions, such as psoriasis and alopecia areata, while highlighting potential treatments like JAK inhibitors and dupilumab that show promise for these comorbidities.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This study reported the expression patterns and potential functions of long non-coding RNAs in the hair follicle cycle of yak, with insights into their sequence conservation between yak and cashmere goat.

This review explores the mechanisms of hair cell death due to factors like noise, ototoxic drugs, and aging and reports no conclusive clinical results; ongoing research may eventually enable preventive treatments for hearing loss.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

This study shows that in a mouse model of Alopecia Areata, selective JAK1 inhibition facilitated hair regrowth and inflammation resolution while potentially offering a better safety profile compared to pan-JAK inhibition.

This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study reviews evidence that in keloid development, transforming growth factor-β (TGF-β) drives fibroblast proliferation and fibrosis not only through the classical Smad-dependent pathway but also via equally important Smad-independent signaling cascades, suggesting these pathways as possible targets for more effective keloid therapies.

This review discusses the complex role of the EDA pathway in vertebrate skeletal development, emphasizing its interaction with other morphogenic pathways to influence skeletal diversity, but reports no new experimental results.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.